Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy. A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy. While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (+/- 0.9) months and a mean overall survival of 17.8 (+/- 1.5) months, an unusually high rate of distant recurrences was observed (62.5%). Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.

Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy / Tuettenberg, J; Grobholz, R; Seiz, M; Brockmann, Ma; Lohr, F; Wenz, F; Vajkoczy, P. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - 135:9(2009), pp. 1239-1244. [10.1007/s00432-009-0565-9]

Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy

Lohr F;
2009

Abstract

Glioblastoma multiforme is the prototype of an angiogenic tumour. Under experimental conditions, anti-angiogenic therapy strategies lead to an increased invasion. Here we report on the pattern of tumour recurrence in glioblastoma patients treated with an anti-angiogenic chemotherapy. A total of 32 patients with glioblastoma multiforme and a residual tumour mass after operation were treated with a continuous low-dose chemotherapy with temozolomide and a COX-II inhibitor, a presumably anti-angiogenic therapy. While anti-tumour activity of this therapy regimen was excellent with a mean overall time to progression of 10.4 (+/- 0.9) months and a mean overall survival of 17.8 (+/- 1.5) months, an unusually high rate of distant recurrences was observed (62.5%). Patients treated with an anti-angiogenic chemotherapy experience distant recurrences at a higher rate than reported for conventional therapies. This may reflect an anti-angiogenic therapy-induced activation of glioma invasion confirming similar recently published experimental results.
135
9
1239
1244
Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy / Tuettenberg, J; Grobholz, R; Seiz, M; Brockmann, Ma; Lohr, F; Wenz, F; Vajkoczy, P. - In: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. - ISSN 0171-5216. - 135:9(2009), pp. 1239-1244. [10.1007/s00432-009-0565-9]
Tuettenberg, J; Grobholz, R; Seiz, M; Brockmann, Ma; Lohr, F; Wenz, F; Vajkoczy, P
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1172369
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact